Happy holidays! Please be advised that in-transit patient samples will be held by the carrier on Dec. 25 and received by our lab the next day. Kit orders placed on Dec. 25 will be sent on Dec. 26. Our genetic counseling services, client services, and billing services will be unavailable Dec. 24-25; please leave us a message at 888-729-1206 or support@genedx.com and we will respond when we return.

Starting with exome can find answers sooner.

Ordering exome as a first-line test can expedite diagnosis to inform prognosis, identify support needs, and connect families with gene-related support groups and resources sooner.

74% of patients with autism spectrum disorder (ASD) also experience co-occurring conditions such as intellectual disability and epilepsy.1

Exome is more likely to deliver a genetic diagnosis for patients with ASD

For patients with both ASD and a co-occurring condition, the diagnostic rate is even higher.

Up to 37% diagnostic yield for patients with autism who present with additional clinical features such as intellectual disability, developmental delay, congenital anomalies, and epilepsy4-6

Get the big picture with exome.

GeneDx offers three exome sequencing options: XomeDx®, XomeDx® Plus, and XomeDxXpress®.

Exome finds answers that other tests can miss.

In a study of more than 18,000 patients with autism who received exome sequencing,6 90% had at least one prior negative genetic test, suggesting that previous tests did not resolve all clinical questions.

Recommended as a first-line test

Guidelines recommend exome as a first-line test for patients with conditions that often co-occur with ASD.

The American College of Medical Genetics and Genomics (ACMG) recommends exome or genome as a first-tier test for individuals with developmental delay, intellectual disability, and congenital anomalies.7

The National Society of Genetic Counselors (NSGC) recommends exome or genome for all individuals with unexplained epilepsy. This guideline is endorsed by the American Epilepsy Society (AES).8

Implications to clinical practice

Meet Oliver*

Oliver didn’t meet normal toddler milestones, including speaking and walking. He was identified to have autism spectrum disorder and expressive language delay.

With comprehensive care from start to finish, GeneDx offers more than a test result.

Experience the GeneDx difference and help your patients find answers.  

*Fictionalized case study for illustrative purposes only

References

  1. Khachadourian V, et al. Transl Psychiatry. 2023 Feb 25;13(1):71.
  2. Arteche-López A, et al. Genes. 2021(12):560.
  3. Ní Ghrálaigh F, et al. J Autism Dev Disord. 2023 Jan;53(1):484-488.
  4. Srivastava S, et al. Genet Med. 2019 Nov;21(11):2413–2421.
  5. Tammimies K, et al. JAMA. 2015 Sep 1;314(9):895-903.
  6. Lindy A, et al. Evaluation of 18,911 individuals with autism reveals that exome analysis provides higher diagnostic rates and reduced time to diagnosis than traditional testing strategies. Poster presented at: AAN 2022 Annual Meeting; April 24-26, 2022; Seattle, WA.
  7. Manickam K, et al. Genet Med. 2021;23(11):2029-2037.
  8. Smith L, et al. J Genet Couns. 2023 Apr;32(2):266-280.